ReviewScientifica2025
Probiotics Supplementation in Tuberculosis: A Scoping Review.
Review in Scientifica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This scoping review aims to synthesize the current clinical evidence on probiotics used in tuberculosis (TB). Systematic literature searches were conducted across PubMed, Scopus, and Embase databases to identify all studies using probiotics in TB. A total of six studies conducted between 2016 and 2023 were found and included in this review. All the studies incorporated probiotics supplementation not beyond the intensive phase of antitubercular therapy (ATT), ranging from three to eight weeks. Five out of six included studies focused on pulmonary TB. Probiotics alleviate adverse gastrointestinal and hepatic drug reactions, modulate gut microbiota, enhance barrier function, and influence immune responses. Therefore, probiotics are a potential adjunct therapy during the intensive phase of ATT. However, their long-term effects remain unexplored, highlighting the future research scope for well-designed longitudinal studies to explore their sustained benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.